<DOC>
	<DOCNO>NCT03026842</DOCNO>
	<brief_summary>Acute myeloid leukemia ( AML ) common hematological malignancy adult patient leukemia , ( 8 ; 21 ) AML account substantial proportion AML . AML patient ( 8 ; 21 ) posse favorable outcome 3 - 4 course high dose cytarabine ( 3 g/m2 ) standard consolidation therapy patient 5-year overall survival approximately 60 % . In China , intermediate dose cytarabine ( 1 - 2 g/m2 ) use consolidation therapy due toxicity . After 3 - 4 course cytarabine consolidation , maintenance therapy perform conventional chemotherapy 5-year overall survival approximately 60 % well . However , continuous chemotherapy may cause toxicity inhibit patient ' immune response . Exploring new drug maintenance therapy urgently need . Decitabine potent ability inhibit proliferation induce apoptosis AML1-ETO positive leukemia cell line . Furthermore , immunomodulatory effect decitabine also report several study . In study , investigator plan carry prospective , multicenter , randomize , control trail compare decitabine versus conventional chemotherapy maintenance therapy patient AML ( 8 ; 21 ) . Results trial may optimize treatment AML patient ( 8 ; 21 ) set intermediate dose cytarabine consolidation .</brief_summary>
	<brief_title>Decitabine Versus Conventional Chemotherapy Maintenance Therapy Acute Myeloid Leukemia With ( 8 ; 21 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Aclacinomycins</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Aclarubicin</mesh_term>
	<criteria>1 . Patients adults age ≥18 ≤60 year 2 . Patients diagnose AML ( 8 ; 21 ) 3 . Continuous complete remission induction consolidation therapy 3 4 course high dose cytarabine ( 2 g/m^2 ) 4 . Patients whose aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 2.5 time higher normal upper limit , total bilirubin ≤ 3.0 mg/dl , serum creatinine ≤ 2.0 mg/dl . 5 . Subjects sign informed consent , indicate understood purpose , procedure potential benefit trial willing participate trial . 1 . Pregnant lactating woman . 2 . ECOG performance status score &gt; 2 . 3 . Patients candidate hematopoietic stem cell transplantation . 4 . Patients history use azacitidine decitabine . 5 . Patients mental disorder completely cooperate treatment follow . 6 . Subjects allergic decitabine vehicle . 7 . Patients receive immunotherapy . 8 . Patients also organ malignant tumor . 9 . Participating clinical research period . 10 . The researcher estimate patient enter clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>